GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has announced the granting of equity awards to 27 newly hired non-executive employees. The awards consist of restricted stock units (RSUs) totaling 47,150 shares of GRAIL's common stock.
The RSUs were granted under GRAIL's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule spans approximately four years, with 25% vesting on August 31, 2026, and the remaining portions vesting annually thereafter, contingent on continued employment.
GRAIL (NASDAQ: GRAL), societ脿 del settore sanitario specializzata nella diagnosi precoce del cancro, ha comunicato l'assegnazione di premi in azioni a 27 nuovi dipendenti non dirigenti. Gli incentivi consistono in unit脿 di azioni vincolate (RSU) per un totale di 47.150 azioni ordinarie di GRAIL.
Le RSU sono state concesse ai sensi del Piano di Incentivazione Azionaria di Induzione di GRAIL, in conformit脿 con la Regola di quotazione Nasdaq 5635(c)(4). Il piano di maturazione copre circa quattro anni, con il 25% che matura il 31 agosto 2026 e le quote rimanenti che maturano annualmente successivamente, subordinatamente al mantenimento dell'impiego.
GRAIL (NASDAQ: GRAL), una empresa sanitaria centrada en la detecci贸n temprana del c谩ncer, ha anunciado la concesi贸n de premios en acciones a 27 empleados no ejecutivos reci茅n contratados. Los premios consisten en unidades de acciones restringidas (RSU) por un total de 47.150 acciones ordinarias de GRAIL.
Las RSU se otorgaron conforme al Plan de Incentivos de Capital por Inducci贸n de GRAIL, de acuerdo con la Norma de Cotizaci贸n Nasdaq 5635(c)(4). El calendario de consolidaci贸n se extiende aproximadamente cuatro a帽os, con el 25% que se consolida el 31 de agosto de 2026 y las porciones restantes que se consolidan anualmente despu茅s, condicionadas a la continuidad en el empleo.
GRAIL (NASDAQ: GRAL)鞚� 臁瓣赴 鞎� 瓴�於滌棎 欤茧牓頃橂姅 項姢旒�鞏� 旮办梾鞙茧, 鞁犼窚 牍勳瀯鞗� 歆侅洂 27氇�鞐愱矊 欤检嫕 氤挫儊(鞐愳考韹� 鞏挫泴霌�)鞚� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. 頃措嫻 氤挫儊鞚� GRAIL 氤错喌欤检棎 雽�頃� 鞝滍暅攵� 欤检嫕 雼渼(RSU) 齑� 47,150欤�搿� 甑劚霅╇媹雼�.
鞚� RSU電� Nasdaq 靸侅灔攴滌爼 5635(c)(4)鞐� 霐半澕 GRAIL鞚� 鞙犾澑(Inducement) 欤检嫕 鞚胳劶韹半笇 頂岆灉 頃橃棎 攵�鞐悩鞐堨姷雼堧嫟. 氩犾姢韺� 鞚检爼鞚� 鞎� 4雲勳棎 瓯胳硱 歆勴枆霅橂┌, 25%電� 2026雲� 8鞗� 31鞚检棎 氩犾姢韸�霅橁碃 雮橂ǜ歆�電� 瓿勳啀 瓿犾毄 臁瓣贝鞚� 於╈”頃� 瓴届毎 鞚错泟 毵る厔 氩犾姢韸鸽惄雼堧嫟.
GRAIL (NASDAQ: GRAL), une entreprise de sant茅 sp茅cialis茅e dans la d茅tection pr茅coce du cancer, a annonc茅 l'attribution d'attributions d'actions 脿 27 employ茅s non cadres nouvellement embauch茅s. Les attributions prennent la forme d'unit茅s d'actions restreintes (RSU) pour un total de 47 150 actions ordinaires de GRAIL.
Les RSU ont 茅t茅 accord茅es dans le cadre du Plan d'incitation en actions d'inducement de GRAIL, conform茅ment 脿 la r猫gle de cotation Nasdaq 5635(c)(4). Le calendrier d'acquisition s'茅tend sur environ quatre ans, avec 25 % acqu茅rables le 31 ao没t 2026 et les parts restantes acqu茅rables chaque ann茅e par la suite, sous r茅serve de la poursuite de l'emploi.
GRAIL (NASDAQ: GRAL), ein Gesundheitsunternehmen mit Schwerpunkt auf Fr眉herkennung von Krebs, hat die Gew盲hrung von Aktienzuteilungen an 27 neu eingestellte nicht-exekutive Mitarbeiter bekanntgegeben. Die Zuteilungen bestehen aus Restricted Stock Units (RSUs) in H枚he von insgesamt 47.150 Aktien der GRAIL-Stammaktien.
Die RSUs wurden im Rahmen des Inducement Equity Incentive Plan von GRAIL gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4) gew盲hrt. Der Vesting-Zeitplan erstreckt sich 眉ber rund vier Jahre, wobei 25 % am 31. August 2026 vesten und die verbleibenden Anteile anschlie脽end j盲hrlich vesten, abh盲ngig von fortgesetzter Besch盲ftigung.
- None.
- None.
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over an approximately four year period, with
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit .
View original content to download multimedia:
SOURCE GRAIL, Inc.
FAQ
What equity awards did GRAIL (NASDAQ: GRAL) announce on August 29, 2025?
How will the GRAIL RSUs vest for new employees?
Under what plan were GRAIL's inducement grants issued?
Who is eligible for GRAIL's inducement equity awards?
